drugset / Trial / NCT07697040
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single-arm, single-center Phase Ib clinical trial of Becotatug Vedotin in combination with cisplatin and concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma. The primary objectives are to investigate the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended Phase II dose (RP2D) of Becotatug Vedotin in combination with cisplatin and concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma. The secondary objectives are to assess the efficacy and safety of this combination regimen.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2029-07-01
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | Becotatug Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Becotatug Vedotin | Monoclonal antibody | 2.3 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |